CARLSBAD, Calif., May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. The replay will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com or follow us on Twitter @ionispharma.
| Last Trade: | US$35.63 |
| Daily Change: | 0.04 0.11 |
| Daily Volume: | 3,594,591 |
| Market Cap: | US$5.630B |
November 07, 2024 November 06, 2024 November 06, 2024 November 04, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
